Cost-benefit of Dapagliflozin versus Sacubitril/Valsartan in HFrEF

Abstract

Background: Heart failure is a progressive cardiovascular pathology that affects millions of people regardless of region, being one of the main causes of death and representing a serious global health problem. As a consequence of scientific advances, it has been possible for patients to experience a longer course of the disease, increasing health costs that threaten to double in the coming years. In recent years, new drugs have been incorporated for the treatment of advanced stages, such as heart failure with reduced ejection fraction. The drugs included are Dapagliflozin as an adjunct to standard treatment and Sacubitril/Valsartan to replace angiotensinconverting enzyme inhibitors in addition to standard treatment. Material and methods: An exhaustive search of articles published in the Pubmed and Google Scholar search engines was carried out, using those that analyzed and compared the cost-benefit of both drugs. Results: Four articles that met all the criteria were included. Conclusion: Dapagliflozin was more value for money in preventing heart failure events compared to Sacubitril/Valsartan especially in diabetic patients and in countries where the price of Dapagliflozin is significantly lower than Sacubitril/Valsartan.